NY-Z-CAPITAL-PARTNERS
6.12.2022 14:41:34 CET | Business Wire | Press release
Z Capital Partners, L.L.C., the private equity fund management arm of Z Capital Group, L.L.C. ("ZCG"), a leading privately held merchant bank, today announced that affiliates of ZCG have acquired Universal Marine Medical Supply International (“Unimed” or the “Company”), the leading global provider of pharmaceutical and medical solutions to the maritime industry, serving both commercial and cruise end markets. Financial terms of the transaction were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221206005652/en/
Unimed provides a wide range of mission-critical medical and clinical supplies, including oxygen, surgery equipment, vaccines and pharmaceutical products, in addition to services such as oversight of procurement and replenishment, compliance audit and advisory, and clinical facilities management. The Company currently serves approximately 10,000 ships per year from 10 worldwide offices and access to over 2,000 ports, making Unimed the largest and most knowledgeable global operator within a highly fragmented sector of the maritime services industry.
Medical standards in the maritime industry are highly regulated, and ship operators can face severe consequences for lack of compliance with international standards and Flag of Convenience requirements. As the largest operator in the industry, Unimed is uniquely positioned to provide customers global just-in-time delivery, inventory management and decades of compliance experience with global maritime medical standards.
Under the ownership of the ZCG affiliates, Unimed will expand into the global areas of marine markets, including super yachts, yacht management companies and manufacturers, while continuing to expand and enhance medical supplies and services to cruise and commercial vessels, including tankers, cargo and freighters.
“Unimed has built a reputation for providing clients with exceptional value and essential, high-quality medical services, and there are a number of compelling opportunities in today’s fragmented maritime services market to grow its customer base and introduce new innovations,” said James Zenni, Founder, President and Chief Executive Officer of ZCG. “With Alan Kessman and the Unimed team, we look forward to leveraging new technologies and ZCG’s deep operational expertise to pursue the vast white space opportunities, further enhance customer service and ensure the health, safety and compliance of even more ships.”
“As we look to expand Unimed’s premier services to additional areas of marine traffic, having a partner with the resources, expertise and track record to help our business accelerate growth is invaluable,” said Alan Kessman, Chief Executive Officer of Unimed. “We have a long track record of innovation – including introducing the industry’s first subscription model in 2018 – and this partnership with ZCG will enable us to build on that momentum and reach new levels of success.”
About Unimed
Unimed is the industry leader in medical supply, equipment and oxygen distribution to global maritime industries, specializing in the delivery of integrated healthcare and safety supply chain logistical solutions to clients worldwide.
For more information, please visit https://universalmarinemedical.com/.
About ZCG
ZCG is a leading, privately held merchant bank comprised of private markets asset management, business consulting services, technology development and solutions.
For almost 30 years, ZCG Principals have invested approximately $30 billion and have industry leading track records in private equity and credit.
ZCG has approximately $5.2B of AUM in asset management and its investors are some of the largest and most sophisticated global institutional investors including pension funds, endowments, foundations, sovereign wealth funds, central banks, and insurance companies.
ZCG has a global team comprised of over 325 professionals. For more information, please visit www.zcg.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005652/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
